Watchman outcomes comparing post-implantation anticoagulation with warfarin versus direct oral anticoagulants
Authors:
- 5 June 2020
- journal article
- research article
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 61 (1) , 137-144
Abstract
Purpose As left atrial appendage occlusion devices (LAAO) implantation rates grow, continued evaluation on best patient practices is important. We report pooled Watchman outcomes at a multicenter Texas healthcare system with an emphasis on clinical outcomes and post-implantation anticoagulation with direct oral anticoagulants (DOACs) versus warfarin. Methods Data for 163 patients with atrial fibrillation (AF) undergoing Watchman implantation was collected via retrospective chart review between June 2016 and June 2018. A Fisher’s exact test was utilized to evaluate associations in bivariate comparisons of categorical data. Tests of non-inferiority, applied between DOACs and warfarin, utilized a ratio of 2. Results Outcomes were significant for similar rates of stroke, disabling stroke, major bleeds, and all-cause mortality when compared to published clinical trials. Most patients with cerebrovascular events were found to have >5 mm peri-device leaks (PDLs), were on warfarin at the time of the event (75%), and all occurred within the first 6 months post implant. A significant number of patients were discharged on DOACs (42%). DOACs were shown to be non-inferior to warfarin with respect to stroke (p = 0.0048), disabling stroke (p = 0.0383), gastrointestinal bleeding (p = 0.0287), mortality (p = 0.0165), and combined adverse outcomes (p = 0.0040). DOACs were associated with less combined adverse outcomes (p = 0.021). Conclusion Our findings suggest that additional imaging or aggressive management of PDLs in Watchman recipients within the initial 6-month follow-up may aid in reducing stroke rates. Additionally, anticoagulation with DOACs’ post Watchman implantation was found non-inferior to warfarin, with some evidence of lower risk for adverse outcomes favoring DOACs.Keywords
This publication has 26 references indexed in Scilit:
- Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman deviceHeart Rhythm, 2017
- Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapyInternational Journal of Cardiology, 2016
- Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implicationsHeart Rhythm, 2015
- Cardiac CT angiography for device surveillance after endovascular left atrial appendage closureEuropean Heart Journal - Cardiovascular Imaging, 2015
- New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial FibrillationInternational Journal of Medical Sciences, 2014
- The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial FibrillationJACC, 2012
- Safety of Percutaneous Left Atrial Appendage ClosureCirculation, 2011
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based ApproachChest, 2010
- Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation J-RHYTHM StudyCirculation Journal, 2009
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002